Richard T Silver
Overview
Explore the profile of Richard T Silver including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
6742
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ghalehsari N, Castillo Tokumori F, Chen Z, Liu M, Mayer S, Zeinah G, et al.
Transplant Cell Ther
. 2024 Sep;
30(11):1100.e1-1100.e11.
PMID: 39243817
Despite the established potentially curative role of allogeneic hematopoietic cell transplantation (allo-HCT) in managing myelofibrosis (MF), the choice of alternative donors for patients lacking matched donors remains a challenge, and...
2.
Abu-Zeinah G, Qin A, Gill H, Komatsu N, Mascarenhas J, Shih W, et al.
Ann Hematol
. 2024 Aug;
103(9):3573-3583.
PMID: 39145781
Primary myelofibrosis (PMF) is the most aggressive of the myeloproliferative neoplasms and patients require greater attention and likely require earlier therapeutic intervention. Currently approved treatment options are limited in their...
3.
Abu-Zeinah G, Erdos K, Lee N, Lebbe A, Bouhali I, Khalid M, et al.
Blood Cancer J
. 2024 Jun;
14(1):103.
PMID: 38918372
No abstract available.
4.
Chamseddine R, Savenkov O, Rana S, Khalid M, Silver R, Kucine N, et al.
Blood Adv
. 2024 Mar;
8(10):2520-2526.
PMID: 38507746
Cytoreductive therapy is not routinely recommended for younger patients with polycythemia vera (PV) due to concern that treatment toxicity may outweigh therapeutic benefits. However, no systematic data support this approach....
5.
Mora B, Maffioli M, Rumi E, Guglielmelli P, Caramella M, Kuykendall A, et al.
EJHaem
. 2023 Aug;
4(3):679-689.
PMID: 37601878
Myelofibrosis (MF) is a clonal malignancy frequently characterized by anemia and in 10%-20% of cases it can evolve into blast phase (BP). Anemia in MF is associated with reduced survival...
6.
Silver R, Abu-Zeinah G
Expert Rev Hematol
. 2023 Apr;
16(4):253-266.
PMID: 37013802
Introduction: Significant advances have been made in the diagnosis and management of patients with polycythemia vera (PV) over the past two decades, but a few important issues remain, either overlooked...
7.
Silver R, Erdos K, Taylor 3rd E, Scandura J, Abu-Zeinah G
Leukemia
. 2022 Dec;
37(3):691-694.
PMID: 36550213
No abstract available.
8.
Mora B, Guglielmelli P, Kuykendall A, Rumi E, Maffioli M, Palandri F, et al.
Leukemia
. 2022 Aug;
36(10):2453-2460.
PMID: 36042316
Patients with Philadelphia-negative myeloproliferative neoplasms are at high risk of thrombotic events (TEs). Predisposing factors have been identified in essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (primary MF,...
9.
Abu-Zeinah G, Di Giandomenico S, Choi D, Cruz T, Erdos K, Taylor E, et al.
Blood Adv
. 2022 Jul;
6(18):5477-5481.
PMID: 35789232
No abstract available.
10.
Abu-Zeinah K, Saadeh K, Silver R, Scandura J, Abu-Zeinah G
Leuk Lymphoma
. 2022 May;
64(3):725-729.
PMID: 35532314
No abstract available.